NASONEX SUMMARY
Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid.
Treatment of Allergic Rhinitis
NASONEX® Nasal Spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis
NASONEX Nasal Spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Prophylaxis of Seasonal Allergic Rhinitis
NASONEX Nasal Spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older.
Treatment of Nasal Polyps
NASONEX Nasal Spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Nasonex (Mometasone Nasal)
Hay Fever (Allergic Rhinitis)
Source: MedicineNet Allergic Cascade Specialty [2016.10.07]
Title: Hay Fever (Allergic Rhinitis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/7/2016 12:00:00 AM
Published Studies Related to Nasonex (Mometasone Nasal)
Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. [2011.10]
OBJECTIVE: To assess the effects of long-term mometasone furoate delivered via a dry powder inhaler (MF-DPI) on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma... CONCLUSIONS: One year of treatment with a total daily dose of 100 mug of MF-DPI in the morning resulted in no significant difference, whereas a total daily dose of 200 mug of MF-DPI was associated with some changes in growth velocity when compared with placebo. The differences in growth velocity, and the absence of drug-related cortisol effects, support the use of a total daily dose of 100 mug of MF-DPI in children aged 4-9 years with mild persistent asthma.
Dysphagia and quality of life may improve with mometasone treatment in patients with eosinophilic esophagitis: a pilot study. [2011.10]
OBJECTIVE: The treatment of adult patients with eosinophilic esophagitis remains challenging. The aim was to assess dysphagia and health-related quality of life (HRQL) using validated scales and questionnaires before and after treatment with mometasone furoate... CONCLUSION: The dysphagia and impaired HRQL found in untreated patients with eosinophilic esophagitis improved significantly after 2 months of mometasone furoate treatment. A randomized placebo-controlled trial is warranted to assess causality. The scales and questionnaires used are sensitive instruments appropriate for symptom surveillance in individuals with eosinophilic esophagitis.
Application of mometasone spray to reduce sore throat after tracheal intubation. [2011.08]
CONCLUSION: Application of mometasone spray reduces postoperative sore throat after tracheal intubation.
The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. [2011.06]
BACKGROUND: The efficacy of oral montelukast in chronic asthma is well established. Montelukast is also an effective adjunctive therapy to inhaled corticosteroids (ICS) in asthma uncontrolled on ICS alone. Inhaled montelukast was recently shown to provide significant bronchodilation compared with placebo in patients with chronic asthma. The purpose of this study was to evaluate the efficacy of inhaled montelukast added to inhaled mometasone... CONCLUSION: Inhaled montelukast plus inhaled mometasone was significantly more effective than placebo plus inhaled mometasone in improving FEV(1), symptoms, asthma control, and blood eosinophil count.
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. [2011.04.01]
CONCLUSION: Patients receiving daily MMF during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Nasonex (Mometasone Nasal)
Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED) [Terminated]
This is a randomized, double-blind, placebo-controlled study to document the long-term
effect of treatment with mometasone furoate nasal spray in moderate to severe adenoids
hypertrophy as reflected by the need for removal of the adenoids within one year of the
treatment regimen. Subjects will be assigned treated with either mometasone furoate nasal
spray or placebo for 3 months. Subjects will be followed for an addition 12 months. Serious
AEs will be followed starting first dose-till 30 days after study treatment period
completion.
This study was terminated - Please see "P04367 - Lebanon"
Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy [Withdrawn]
Obstructive sleep apnea (OSA) in children is a disorder of breathing during sleep
characterized by prolonged partial upper airway obstruction and/or intermittent complete
obstruction (obstructive apnea) that disrupts normal breathing during sleep1. The condition
occurs in 2-5% of children and can occur at any age, but it is most common in children
between the ages of 2 to 62,3. Untreated OSA is associated with lung disease, heart
disease, growth delay, poor learning and behavioral problems such as inattention and
hyperactivity. The most common underlying risk factor for the development of OSA is
enlargement of tonsils and adenoids. Given the potential risk of complications associated
with surgery of the tonsils and adenoids, medications to shrink the adenoids without
requiring surgery have been considered, in particular intranasal corticosteroids (INCSs)
which is a nose spray. A recent Cochrane systematic review suggested a short-term benefit
of INCSs in children with mild to moderate OSA4. The authors recommended that further
randomised controlled studies were required to evaluate the efficacy of INCSs in children
with OSA. In particular they recommended that future studies should employ sleep studies to
look for any improvement with INCSs, and should include children with more severe OSA, as
these are the patients at the greatest risk of complications of surgery and would benefit
most from a non-surgical treatment. The purpose of this study is therefore to explore the
efficacy of INCSs in children with the full spectrum of OSA severity, including sleep study
analysis., and longer term follow-up.
A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED) [Completed]
This is a multicenter, randomized, double-blind within the dose level, parallel group
comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to
examine the minimal effective dose, the recommended dose, and the dosing regimen.
Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis [Completed]
To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal
Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal
Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207) [Completed]
This was a one-day single dose trial conducted to compare patient's preference for Nasonex®
(mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2
sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to
take one dose of the opposite medication. Questionnaires were given to each patient after
each drug dose to evaluate patient product preference.
Reports of Suspected Nasonex (Mometasone Nasal) Side Effects
Drug Dose Omission (20),
Product Quality Issue (16),
Epistaxis (14),
Dyspnoea (14),
Cataract (14),
NO Adverse Event (14),
Malaise (13),
Glaucoma (12),
Headache (11),
Drug Ineffective (9), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 12 ratings/reviews, Nasonex has an overall score of 7.92. The effectiveness score is 8.67 and the side effect score is 7.83. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Nasonex review by 41 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | congestion |
| Dosage & duration: | | 2 sprays 2 times a day (dosage frequency: 2times every day) for the period of 6 months |
| Other conditions: | | sneezing |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Able to breath at night, less sneezing. I woke up with less nasal stufiness and felt clear headed. I also appreciated the moisturizing glycerin in Nasonex. I have a extremely dry nasal mucosa so there was definitely a benefit to that. |
| Side effects: | | Did not have any side effects and I felt extremely good during the allergy season. I actually enjoyed the moisterizing glycerin in my nose. |
| Comments: | | Use in the morning and evening in the spring allergy season. Continue to use even if symptoms disapear and 2 to 4 weeks prior to full blown allergy symptoms. |
|
| | Nasonex review by 42 year old male patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | sinusitis |
| Dosage & duration: | | Aqueous Nasal Spray 0.05% (dosage frequency: twice a day) for the period of 4 weeks |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Relieved symptoms of itchy runny nose providing relief from discomfort |
| Side effects: | | None |
| Comments: | | Use inhaler twice a day once in the morning and once in the evening for a period of four weeks. It took approximately five days to week before lasting relief was obtained. Continuous use prevented the condition from recurring. Condition occurred on a seasonal basis in the mid fall and mid spring period. No symptons in Winter or Summer. |
|
| | Nasonex review by 64 year old male patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Extremely Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | swollen passages from allergies |
| Dosage & duration: | | 1puff in ea nostril ,2x daily (dosage frequency: 1 puff in ea nostril 2x dialy) for the period of two years |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | drug helped alleviate stuffy feeling without much notice of any side effects. |
| Side effects: | | in the past year i have been having reoccurring pink eye/blifuritis bouts.
around the same tine i have been plagued with repeated episodes of itching, strange rashes all over my body and my hands are full of unsightly cracks,sores and redness. now the episodes are getting closer and closer and worse each time.
|
| Comments: | | topical and internal steroid meds and antibiotics to avert infection, all help just until the next outbreak which after the last bout was about a week or so. |
|
|
|
Page last updated: 2016-10-07
|
